Omnicell, Inc. $OMCL Stock Holdings Raised by Redmond Asset Management LLC

Key Points

• Redmond Asset Management LLC increased its stake in Omnicell, Inc. by 16.4% during Q1, owning 141,111 shares valued at approximately $4.93 million.
• Several other hedge funds, including Summit Investment Advisors Inc. and Diversified Trust Co., have also adjusted their stakes, indicating a growing interest from institutional investors who own 97.70% of the company's stock.
• Omnicell reported earnings of $0.45 EPS for the quarter, exceeding estimates, with revenue of $290.56 million and a year-over-year revenue increase of 5.0%.

Redmond Asset Management LLC boosted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 16.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 141,111 shares of the company's stock after buying an additional 19,902 shares during the quarter. Omnicell accounts for approximately 1.3% of Redmond Asset Management LLC's portfolio, making the stock its 18th largest holding. Redmond Asset Management LLC owned 0.30% of Omnicell worth $4,933,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $37,000. Point72 Hong Kong Ltd acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $101,000. Corton Capital Inc. acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $208,000. Summit Investment Advisors Inc. grew its position in shares of Omnicell by 6.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock valued at $213,000 after purchasing an additional 307 shares during the last quarter. Finally, Caption Management LLC acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $223,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Piper Sandler lowered their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Bank of America raised their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company raised their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Trading Down 1.0%

NASDAQ:OMCL traded down $0.3240 during trading hours on Wednesday, reaching $31.5860. 131,366 shares of the company were exchanged, compared to its average volume of 566,889. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 63.14, a PEG ratio of 9.23 and a beta of 0.78. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74. The stock has a 50 day simple moving average of $29.46 and a 200 day simple moving average of $32.07.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. During the same quarter last year, the firm posted $0.51 EPS. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.